When you go to “COOKIES INCL. ALLOW US SERVICES” click, you agree to the storage of cookies on your device to improve website navigation, analyze site usage, and support our marketing efforts. For more information, see our Privacy statement.

Spherox is the only advanced therapy (ATMP) drug approved by EMA for the treatment of cartilage damage. It is a personalized cell therapy made from the patient's autologous cartilage tissue. The cells are isolated, multiplied and transplanted in the form of spheroids in order to fully integrate into the existing, healthy cartilage.

233 Transplants in Austria since 2019

99.99% biocompatible thanks to the body's own cells

Spherox uses autologous chondrocytes, which are isolated and multiplied from the patient's own cartilage tissue. This minimizes the risk of rejection reactions

Minimally invasive method

Spheroid transplantation is carried out using minimally invasive techniques

Self-adhesive spheroid technology™

The spheroids stick independently in the cartilage defect and synthesize hyaline-like cartilage

Indication of Spherox for knee cartilage defects

Spherox is indicated for symptomatic joint cartilage defects of the femoral condyles and patella of the knee joint (ICRS grade III or IV) with a defect size of 4-10 cm²

Regeneration of cartilage defects through Spherox transplantation

Defect area

Spherox application

4 months after Spherox transplant

Treatment methods for cartilage damage

Spherox compared to other methods

Balkendiagramm zeigt geeignete Behandlungsmethoden nach Defektgröße: NanoFx für kleine Defekte, HyaloFast für mittelgroße und autologe Chondrozyten-Transplantation (Spherox) für größere Defekte
NanoFx-Logo in Grautönen mit stilisiertem Punktmuster und Kreis, das minimalinvasive Knorpelbehandlungen symbolisiert

Microfracturing (nanoFX®)

  • Suitable for smaller defects up to 2 cm²
  • Mobilizes stem cells from bone marrow to promote cartilage regeneration
HyaloFast-Logo mit stilisierten Pfeilen, die eine kreisförmige Bewegung um den Text symbolisieren

HyaloFast®

  • Suitable for defect sizes of 1 to 4.5 cm²
  • Serves as a framework for stem cells and supports healing
Spherox-Logo in limonengrüner Schrift mit stilisiertem X in Magenta, das Zelltherapie für Knorpelregeneration symbolisiert

Autologous Chondrocyte Transplantation (Spherox)

  • Suitable for defect sizes from 2 cm² to 10 cm²
  • Involves the removal and cultivation of the patient's own cartilage cells, which are then transplanted

Procedure of a Spherox cartilage cell transplant

Step 1

Biopsy

Extraction of small cylinders of healthy cartilage from the affected joint and, in addition, a blood sample for cell cultivation

Step 2

Cultivation

Isolation and multiplication of cartilage cells with addition of patient blood serum to spheroids

Step 3

Transplantation

Introduction of spheroids into the cartilage defect in a second minimally invasive procedure. The spheroids stick independently and form new cartilage tissue, which connects to the existing healthy cartilage.

Step 4

Rehabilitation

An individually adapted rehabilitation plan starts after the transplant and gradually increases the load on the joint up to full resilience

Dr. Wolfgang Zinser about cell therapy & Spherox

Rehabilitation phases after a Spherox transplant

1st — 6th week

proliferation phase

Growth of new cartilage cells in the cartilage defect

During the first few weeks, severe shear forces on the young regenerated material should be avoided at all costs. However, it is necessary to move the joint to nourish the growing cartilage cells, so the following examples of treatment methods are recommended:

  • Gradually increasing the range of motion with knee joint orthosis
  • Passive movement training with CPM splint, 2 x approx. 30 min/day for 6 weeks
  • Controlled physiotherapy with movement exercises
7th — 12th week

Transformation phase

Development of cartilage cells and the formation of type II collagen

Proteoglycans form the cartilage matrix, which is important for the formation of cartilage. The regenerated material now has a sponge-like consistency and is becoming increasingly solid. If the healing process is normal, extensive filling of the cartilage defect can be seen after 3 months. Examples of treatment methods in this phase:

  • Restoring full passive and active range of motion through physiotherapy
  • Gradual increase in stress in the 7th - 8th postoperative week up to full load from the 9th postoperative week
  • Endurance training through stationary cycling (from 8 weeks), crawl swimming and aqua jogging (from 10 weeks)
4th — 6th month

remodeling phase

Increasing strengthening of regenerated cartilage with the formation of protein networks

The transplant now forms a firm connection to the bone and surrounding cartilage line. In this phase, the focus is on muscle training, as well as endurance training, functional and coordination training.

Examples of treatment methods include:

  • Continuation of endurance training with cycling, swimming, aqua jogging, rowing ergometer, stepper, cross trainer, Nordic walking
  • Easy equipment training with a high number of repetitions under physiotherapeutic guidance
From the 7th month

Maturation phase

Large matrix proteins increasingly stabilize regenerated cartilage and form a framework for cartilage cells

The connection to the subchondral bone and the surrounding cartilage is strengthened. Even after the 2nd and 3rd postoperative year, there is still a further improvement in cartilage quality. Examples of advanced treatment methods:

  • Muscle-building training on equipment (dosed, emphasis on the number of repetitions, no load peaks)
  • Cycling, swimming, aqua jogging, rowing ergometer, stepper, cross trainer, Nordic walking, cross-country skiing
  • Jogging on the level from 9 to 12 months depending on the original size of the defect

Spherox studies

The latest study results on Spherox.
Spherox-Logo in limonengrüner Schrift mit stilisiertem X in Magenta, das Zelltherapie für Knorpelregeneration symbolisiert
Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
Safety and Efficacy of Matrix-Associated Autologous Chondrocyte Implantation With Spheroids for Patellofemoral or Tibiofemoral Defects: A 5-Year Follow-up of a Phase 2, Dose-Confirmation Trial
Sustained superiority in KOOS subscores after matrix‑associated chondrocyte implantation using spheroids compared to microfracture
Clinical Trial Results: Prospective, randomised, open label, multicentre Phase-III clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphere® (ACT3D-CS) with microfracture in subjects with cartilage defects of the knee with a defect size between 1 and 4 cm2